Abstract: A gas concentration regulator for use in culture of bacteria, including: (a) an ascorbic acid component; (b) a transition metal catalyst; (c) activated carbon; (d) an alkali metal carbonate or an alkaline earth metal hydroxide; and (e) water, wherein the activated carbon is impregnated with the ascorbic acid component and the water, and an average pore diameter of the activated carbon is 2.0 nm or more.

Abstract: The present disclosure provides for engineered microorganisms and methods of making and using same. The engineered microorganisms as described herein can have a surface display and can be useful as therapeutic agents (e.g., sponges) and biosensors.

Abstract: Provided are a bacterium having a 16S rRNA gene comprising a nucleotide sequence having 98.2% or more identity to the nucleotide sequence represented by SEQ ID NO: 1, and having an ability to degrade a target microorganism, a microbial preparation for degrading a target microorganism, comprising a bacterium (a1), and a method for degrading a target microorganism and a device for degrading a target microorganism using the same. Bacterium (a1) is a bacterium having a 16S rRNA gene comprising a nucleotide sequence having 90% or more identity to the nucleotide sequence represented by SEQ ID NO: 1, and having an ability to degrade a target microorganism.

Abstract: The present application provides engineered glucose dehydrogenase polypeptides having imine reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Abstract: An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.

Abstract: Provided as a mutant of ? glucuronidase suitable for homogeneous immunoassays is a ? glucuronidase mutant, wherein, in the amino acid sequence of Escherichia coli ? glucuronidase, methionine at position 516 is substituted with lysine, and tyrosine at position 517 is unsubstituted or substituted with a non-tyrosine aromatic amino acid.

Abstract: The present invention provides a topical composition having a fermented product of lactic acid bacteria synbiotics as an active ingredient. The fermented product of lactic acid bacteria synbiotics is obtained by performing a fermenting step with lactic acid bacteria and a deactivating step on a fermenting substrate. The lactic acid bacteria are consisting of Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus acidophilus TYCA06. The fermenting substrate includes animal protein, plant protein and/or plant extracts. The aforementioned fermented product of lactic acid bacteria synbiotics can effectively inhibit the growth of Staphylococcus aureus and/or Propionibacterium acnes, and can be used in the topical composition.

Abstract: A combination of probiotics for improving body compositions includes Lacticaseibacillus paracasei S38 and Bacillus coagulans BC198. The combination of probiotics can be a medicine composition, a nutrient supplement, healthy food or a combination thereof. The applications of the combination of probiotics include weight loss, reduction of fat, abatement of appetite, production of butyric acid within intestinal tracts and an increased count of Akkermansia muciniphila or Ruminococcaceae inside intestines.

Abstract: The application relates to a dextran affinity tag and use thereof. The present application provides an affinity tag, which is a segment of dextran binding domain, and can purify a target protein by its affinity with the dextran. The affinity tag of the present application has the advantages of more efficient in preparation and purification, and can be widely used in industrial applications that require protein purification processes.

Abstract: The present disclosure relates to Lactobacillus plantarum NK3 and Bifidobacterium longum NK49, which are novel lactic acid bacteria, and, more particularly, to a composition comprising novel lactic acid bacteria that are useful for the prevention or treatment of female menopausal disorders.

Abstract: The present invention relates to in vitro nanocoatings based on insect corneal designs and methods for producing such nanocoatings. In particular, the present invention relates to in vitro nanocoatings based on the mixture of the corneal protein retinin, retinin-like protein, or cuticular protein with complementary lipids. Furthermore, the present invention relates to simple methods for producing such nanocoatings from recombinant proteins and commercially available lipids.

Abstract: Disclosed herein, are methods of detecting multiple sclerosis in a subject by measuring relative abundances of multiple oral microbiota in sample. Also, disclosed herein are methods of treatment and prophylaxis of MS.

Abstract: Described herein are compositions of collagen and micronized placental tissue components, methods for producing the same and methods for using the same for wound healing, repairing damaged tendons, cosmetic applications and covering biocompatible materials and/or devices.

Abstract: The present invention relates to methods for the preparation of high molecular weight polyhydroxybutyrate (PHB) by culturing Bacillus megaterium strains in a mixture of agri-food wastes, PHB obtained or obtainable by the methods as well as to its use in the preparation of articles such as, for example, soles and/or heels for shoes.

Abstract: The present invention provides a Lactobacillus composition and a use thereof for improving anxiety caused by antibiotics, wherein the Lactobacillus composition comprises Lactobacillus plantarum GMNL-141, Lactobacillus rhamnosus GM-020, Lactobacillus acidophilus GMNL-185, or a combination thereof. The Lactobacillus composition can effectively improve imbalance of an individual's intestinal flora caused by antibiotics to help stabilize and increase species richness and increase the synthesis of mood-stabilizing compounds, including flavonoids, flavonols, isoquinoline alkaloids, niacinamide, nicotinamide, and short-chain fatty acids in intestine, and thus effectively improve antibiotic-induced with anxiety disorders.

Abstract: Provided is a mutant UDG having improved thermal sensitivity compared to a wild-type UDG. The mutant UDG of the presently claimed subject matter having a high thermal sensitivity has no inhibitory effect on the PCR reaction and thus can be advantageously used for the development of PCR/qPCR Premix and particularly PCR diagnostic kits employing UDG which requires the use of relatively low temperature in melting and amplification steps.

Abstract: A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount of Lactobacillus paracasei GMNL-133, an effective amount of Lactobacillus reuteri GMNL-89, and a pharmaceutically acceptable carrier, wherein the Lactobacillus paracasei GMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and the Lactobacillus reuteri GMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

Abstract: Disclosed herein are methods for improving gastrointestinal barrier function, alleviating a gastrointestinal barrier dysfunction-associated disorder, and inhibiting growth of enteric pathogenic bacteria using a composition containing Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115, which are deposited at the China General Microbiological Culture Collection Center (CGMCC) respectively under accession numbers CGMCC 21225, CGMCC 15212, and CGMCC 21840. A number ratio of Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115 ranges from 1:0.2:0.67 to 1:9:9.

Abstract: At least one isolated lactic acid bacteria strains selected from the following: TSP05 (Lactobacillus plantarum), TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri) is provided. The above-mentioned active or inactive lactic acid bacteria strains have a function of hepatoprotection and is used in a form of a food composition or a pharmaceutical composition.

Abstract: Disclosed herein are methods for inhibiting growth of oral pathogenic bacteria and alleviating an oral pathogenic bacteria-associated disorder using a culture of at least one lactic acid bacterial strain selected from the group consisting of Lactobacillus rhamnosus MP108 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 21225, and Lactobacillus paracasei MP137 which is deposited at the CGMCC under an accession number CGMCC 21224.